X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4125) 4125
Publication (214) 214
Book Review (54) 54
Magazine Article (18) 18
Newsletter (15) 15
Book Chapter (14) 14
Conference Proceeding (5) 5
Book / eBook (1) 1
Newspaper Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3317) 3317
isoniazid - adverse effects (1998) 1998
male (1786) 1786
female (1711) 1711
adult (1452) 1452
isoniazid - therapeutic use (1353) 1353
tuberculosis (1227) 1227
isoniazid (1162) 1162
middle aged (1102) 1102
tuberculosis, pulmonary - drug therapy (919) 919
index medicus (908) 908
antitubercular agents - adverse effects (901) 901
antitubercular agents - therapeutic use (756) 756
isoniazid - administration & dosage (662) 662
aged (657) 657
rifampin - adverse effects (625) 625
adolescent (594) 594
rifampin - therapeutic use (580) 580
drug therapy, combination (561) 561
tuberculosis - drug therapy (554) 554
child (437) 437
antitubercular agents - administration & dosage (409) 409
infectious diseases (398) 398
rifampin - administration & dosage (395) 395
chemical and drug induced liver injury - etiology (386) 386
rifampin (384) 384
animals (382) 382
risk factors (343) 343
drug therapy (315) 315
treatment outcome (300) 300
ethambutol - therapeutic use (296) 296
respiratory system (296) 296
medicine, general & internal (295) 295
time factors (294) 294
pharmacology & pharmacy (292) 292
tuberculosis - prevention & control (276) 276
liver - drug effects (270) 270
child, preschool (248) 248
pyrazinamide (248) 248
hepatotoxicity (247) 247
antitubercular agents (244) 244
streptomycin - therapeutic use (230) 230
pulmonary tuberculosis (222) 222
ethambutol - adverse effects (220) 220
pyrazinamide - therapeutic use (218) 218
infant (214) 214
pyrazinamide - adverse effects (212) 212
health aspects (209) 209
therapy (209) 209
drugs (206) 206
mycobacterium tuberculosis - drug effects (206) 206
streptomycin - adverse effects (202) 202
care and treatment (190) 190
tuberculin test (190) 190
mycobacterium-tuberculosis (187) 187
research (187) 187
drug administration schedule (186) 186
retrospective studies (185) 185
rifampicin (185) 185
immunology (178) 178
tuberculosis, pulmonary - prevention & control (175) 175
pyrazinamide - administration & dosage (171) 171
drug interactions (168) 168
chemical and drug induced liver injury (165) 165
drug resistance (165) 165
risk (165) 165
ethambutol - administration & dosage (164) 164
young adult (163) 163
hepatitis (161) 161
isoniazid - pharmacology (161) 161
research article (161) 161
hiv (160) 160
niacin (159) 159
infection (158) 158
microbiology (154) 154
analysis (150) 150
diagnosis (149) 149
nicotinic acids - adverse effects (149) 149
medicine (147) 147
infections (146) 146
mycobacterium tuberculosis (143) 143
patients (141) 141
rats (141) 141
dosage and administration (138) 138
latent tuberculosis - drug therapy (138) 138
liver (138) 138
tuberculosis - epidemiology (138) 138
complications and side effects (137) 137
mycobacterium tuberculosis - isolation & purification (135) 135
follow-up studies (133) 133
prospective studies (133) 133
drug resistance, microbial (132) 132
isoniazid - toxicity (131) 131
mice (131) 131
human immunodeficiency virus--hiv (130) 130
ethambutol (128) 128
isoniazid preventive therapy (128) 128
chemotherapy (125) 125
patient compliance (123) 123
streptomycin - administration & dosage (121) 121
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3254) 3254
French (223) 223
German (217) 217
Russian (100) 100
Japanese (92) 92
Spanish (73) 73
Italian (59) 59
Polish (48) 48
Chinese (17) 17
Dutch (15) 15
Norwegian (12) 12
Romanian (12) 12
Portuguese (11) 11
Czech (8) 8
Korean (5) 5
Danish (4) 4
Hungarian (4) 4
Turkish (4) 4
Bulgarian (3) 3
Finnish (3) 3
Hebrew (3) 3
Swedish (2) 2
Croatian (1) 1
Persian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Human & Experimental Toxicology, ISSN 0960-3271, 6/2017, Volume 36, Issue 6, pp. 616 - 625
Journal Article
Public Health Reports, ISSN 0033-3549, 5/2019, Volume 134, Issue 1_suppl, pp. 71S - 79S
Objectives: In California, about 80% of tuberculosis disease is caused by untreated latent tuberculosis infection (LTBI), and the rate of LTBI is higher among... 
tuberculosis infection | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | 3-month treatment | C VIRUS-INFECTION | RIFAPENTINE | HEPATOTOXICITY | HEALTH | prevention | correctional health care | Prisons | Tuberculosis | Treatment | Inmates of institutions | Infections | Imprisonment | Hepatotoxicity | Patients | Isoniazid | Morbidity
Journal Article
Journal Article
Current Pharmacogenomics and Personalized Medicine, ISSN 1875-6921, 12/2018, Volume 16, Issue 3, p. 210
Background: Tuberculosis is one of the most prevalent infectious diseases. Treatment of tuberculosis requires treatment for a long duration with a combination... 
Drugs | Target recognition | Medical treatment | Medical services | GSTM1 protein | Pyrazinamide | GSTT1 protein | Amine oxidase (flavin-containing) | Side effects | Infectious diseases | Tuberculosis | Annotations | Computation | Computer applications | Docking | Ethambutol | Isoniazid | Rifampin
Journal Article
Journal Article
Drug, Healthcare and Patient Safety, ISSN 1179-1365, 10/2014, Volume 6, pp. 145 - 149
Isoniazid preventative therapy (IPT) is a widely used intervention for treatment of latent tuberculosis infection (LTBI), particularly in patients at high risk... 
Latent tuberculosis infection | Treatment toxicity | Isoniazid preventative therapy | Complications and side effects | Pharmacology, Experimental | Tuberculosis | Drug therapy | Isoniazid | Studies | Hepatitis | Infectious diseases | Alopecia | Baldness | Liver | Tumor necrosis factor-TNF | Systematic review | Infections | Peripheral neuropathy | Patients
Journal Article
CNS Drugs, ISSN 1172-7047, 8/2010, Volume 24, Issue 8, pp. 655 - 667
Nervous system toxicity with current antituberculosis pharmacotherapy is relatively uncommon, although the frequency of the usage of antituberculosis therapy... 
Pharmacotherapy | Neurology | Neurosciences | Medicine & Public Health | Psychiatry | Psychopharmacology | Pyrazinamide, adverse reactions | Aminoglycosides, adverse reactions | Ethambutol, adverse reactions | Antituberculars, adverse reactions | Adverse-drug-reactions | Isoniazid, adverse reactions | Cycloserine, adverse reactions | Metronidazole, adverse reactions | Tuberculosis | Aminosalicylic-acid, adverse reactions | Ethionamide, adverse reactions | Thioacetazone, adverse reactions | Linezolid, adverse reactions | Meropenem, adverse reactions | Rifampicin, adverse reactions | Fluoroquinolones, adverse reactions | Capreomycin, adverse reactions | MYCOBACTERIUM-TUBERCULOSIS | OCULAR ETHAMBUTOL TOXICITY | DRUG-INTERACTIONS | PSYCHIATRY | D-CYCLOSERINE | SCHIZOPHRENIA | AMINOGLYCOSIDE ANTIBIOTICS | CLINICAL NEUROLOGY | SEIZURE | RESISTANCE | PERIPHERAL NEUROPATHY | PHARMACOLOGY & PHARMACY | METRONIDAZOLE | Antitubercular Agents - adverse effects | Humans | Antitubercular Agents - pharmacology | Male | Animals | Mycobacterium tuberculosis | Tuberculosis - drug therapy | Central Nervous System - drug effects | Female | Nervous System Diseases - chemically induced | Antitubercular Agents - poisoning | Antitubercular Agents - therapeutic use | Peripheral Nervous System - drug effects | Complications and side effects | Antitubercular agents | Nervous system diseases | Dosage and administration | Research | Risk factors | Index Medicus
Journal Article
Archives of Dermatological Research, ISSN 0340-3696, 1/2009, Volume 301, Issue 1, pp. 99 - 105
Drug-induced lupus erythematosus (DILE) is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation... 
Drug-induced lupus erythematosus | Antinuclear antibodies (ANA) | Medicine & Public Health | Dermatology | Anti-TNFα-induced lupus | Anti-histone antibodies | Subacute cutaneous drug-induced lupus (SCLE) | Drug reactions | RHEUMATOID-ARTHRITIS | AUTOANTIBODIES | NECROSIS-FACTOR-ALPHA | INDUCTION | DERMATOLOGY | Anti-TNF alpha-induced lupus | THERAPY | AUTOIMMUNITY | INFLIXIMAB | ETANERCEPT | ANTI-TNF-ALPHA | EPIDEMIOLOGY | Antifungal Agents - adverse effects | Antitubercular Agents - adverse effects | Naphthalenes - adverse effects | Antibodies - metabolism | Calcium Channel Blockers - adverse effects | Serositis | Exanthema | Humans | Isoniazid - adverse effects | Interferons - adverse effects | Antihypertensive Agents - administration & dosage | Sodium Chloride Symporter Inhibitors - adverse effects | Arthritis | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Lupus Erythematosus, Systemic - immunology | Sodium Chloride Symporter Inhibitors - administration & dosage | Tumor Necrosis Factor-alpha - immunology | Antibodies - immunology | Lupus Erythematosus, Cutaneous - chemically induced | Procainamide - administration & dosage | Lupus Erythematosus, Cutaneous - immunology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Anti-Arrhythmia Agents - administration & dosage | Procainamide - adverse effects | Antihypertensive Agents - adverse effects | Hydralazine - adverse effects | Isoniazid - administration & dosage | Lupus Erythematosus, Systemic - diagnosis | Interferons - administration & dosage | Hydralazine - administration & dosage | Animals | Anti-Arrhythmia Agents - adverse effects | Naphthalenes - administration & dosage | Calcium Channel Blockers - administration & dosage | Antitubercular Agents - administration & dosage | Lupus Erythematosus, Systemic - chemically induced | Antifungal Agents - administration & dosage | Lupus Erythematosus, Cutaneous - diagnosis | Lupus | Antigen-antibody reactions | Enzymes | Antigens | Biological products | Antibodies | Viral antibodies | Enzyme inhibitors | Systemic lupus erythematosus | Fluocinolone acetonide | Calcium channel blockers | Diuretics | Kidney diseases | Hydralazine | Index Medicus
Journal Article
by Danel, Christine and Moh, Raoul and Gabillard, Delphine and Badje, Anani and Le Carrou, Jérôme and Ouassa, Timothée and Ouattara, Eric and Anzian, Amani and Ntakpé, Jean-Baptiste and Minga, Albert and Kouame, Gérard M and Bouhoussou, Franck and Emieme, Arlette and Kouamé, Antoine and Inwoley, André and Toni, Thomas-D'Aquin and Ahiboh, Hugues and Kabran, Mathieu and Rabe, Cyprien and Sidibé, Baba and Nzunetu, Gustave and Konan, Romuald and Gnokoro, Joachim and Gouesse, Patrice and Messou, Eugène and Dohoun, Lambert and Kamagate, Synali and Yao, Abo and Amon, Solange and Kouame, Amadou-Barenson and Koua, Aboli and Kouamé, Emmanuel and Ndri, Yao and Ba-Gomis, Olivier and Daligou, Marcelle and Ackoundzé, Simplice and Hawerlander, Denise and Ani, Alex and Dembéle, Fassery and Koné, Fatoumata and Guéhi, Calixte and Kanga, Constance and Koule, Serge and Séri, Jonas and Oyebi, Mykayila and Mbakop, Nathalie and Makaila, Olewole and Babatunde, Carole and Babatounde, Nathanael and Bleoué, Gisèle and Tchoutedjem, Mireille and Kouadio, Alain-Claude and Sena, Ghislaine and Yededji, Sahinou-Yediga and Assi, Rodrigue and Bakayoko, Alima and Mahassadi, Alassane and Attia, Alain and Oussou, Armel and Mobio, Max and Bamba, Doféré and Koman, Mesmin and Horo, Apollinaire and Deschamps, Nina and Chenal, Henri and Sassan-Morokro, Madeleine and Konate, Seidou and Aka, Kakou and Aoussi, Eba and Journot, Valérie and Nchot, Célestin and Karcher, Sophie and Chaix, Marie-Laure and Rouzioux, Christine and Sow, Papa-Salif and Perronne, Christian and Girard, Pierre-Marie and Menan, Hervé and Bissagnene, Emmanuel and Kadio, Auguste and Ettiegne-Traore, Virginie and Moh-Semdé, Corinne and Kouame, Abo and Massumbuko, Jean-Marie and Chêne, Geneviève and Dosso, Mireille and Domoua, Serge K and N'Dri-Yoman, Thérèse and Salamon, Roger and Eholié, Serge P and Anglaret, Xavier and The TEMPRANO ANRS 12136 Study Group and TEMPRANO ANRS 12136 Study Group
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 808 - 822
Journal Article